Cytek Biosciences, Inc. (CTKB)
Cytek Biosciences, Inc. (CTKB) from its SEC filings: 2025 revenue $201.5 million (+0% vs the year before), net margin -33%, free cash flow -$8.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Revenue (2025) | $201.5 million |
| Revenue growth | +0% |
| Net income | -$66.5 million |
| Net margin | -33.0% |
| Free cash flow | -$8.8 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +6% |
| Cash | $73.8 million |
| Share count, 1 year | +2% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.